Pfizer · Multi-Quarter Financial Trends

14 quarters · As reported by the company · Amounts in USD billions← PFE

Quarter	Period End	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Net Margin	Free Cash Flow ($B)	EPS	Buybacks ($B)	Dividends ($B)
FY2026 Q2	2026-06-28	15.03	+2.6%	72.8%	—	-0.25	-1.6%	0.30	-0.04	—	—
FY2026 Q1	2026-03-29	14.45	+5.4%	75.4%	—	2.69	18.6%	2.18	0.47	—	—
FY2025 Q4	2025-12-31	17.56	−1.2%	70.0%	—	-1.65	-9.4%	4.50	-0.29	—	—
FY2025 Q3	2025-09-28	16.65	−5.9%	74.9%	—	3.54	21.3%	4.00	0.62	—	—
FY2025 Q2	2025-06-29	14.65	+10.3%	74.2%	—	2.91	19.9%	-1.20	0.51	—	—
FY2025 Q1	2025-03-30	13.72	−7.8%	79.3%	—	2.97	21.6%	1.77	0.52	—	—
FY2024 Q4	2024-12-31	17.76	+31.7%	66.7%	—	0.41	2.3%	5.80	0.07	—	—
FY2024 Q3	2024-09-29	17.70	+36.1%	70.3%	—	4.47	25.2%	6.06	0.78	—	—
FY2024 Q2	2024-06-30	13.28	−28.1%	75.2%	—	0.04	0.3%	-2.42	0.01	—	—
FY2024 Q1	2024-03-31	14.88	—	77.3%	—	3.12	20.9%	0.39	0.55	—	—
FY2023 Q4	2023-10-01	13.49	−40.4%	31.3%	—	-2.38	-17.7%	2.65	-0.42	0.00	—
FY2023 Q3	2023-07-02	13.01	—	75.1%	—	2.33	17.9%	-2.12	0.41	0.00	—
FY2023 Q2	2023-04-02	18.49	—	73.6%	—	5.54	30.0%	0.07	0.97	0.00	—
FY2022 Q4	2022-10-02	22.64	—	73.2%	—	8.61	38.0%	5.13	1.51	0.00	—

Quarterly figures come from the company's 10-Q and 10-K filings. The fourth quarter is derived as the full year minus the first three quarters; cash flow items are converted from fiscal year-to-date totals into single quarters.